Media headlines about GlycoMimetics (NASDAQ:GLYC) have trended somewhat positive on Tuesday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. GlycoMimetics earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.2705923017146 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern’s analysis:

GLYC has been the topic of several analyst reports. ValuEngine raised GlycoMimetics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. SunTrust Banks reaffirmed a “buy” rating and set a $21.00 target price on shares of GlycoMimetics in a report on Wednesday, October 4th. Zacks Investment Research raised GlycoMimetics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Friday, October 6th. Roth Capital initiated coverage on GlycoMimetics in a report on Monday, October 23rd. They set a “buy” rating and a $25.00 target price on the stock. Finally, Jefferies Group reaffirmed a “buy” rating and set a $16.00 target price on shares of GlycoMimetics in a report on Thursday, October 26th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. GlycoMimetics currently has a consensus rating of “Buy” and an average target price of $20.17.

Shares of GlycoMimetics (GLYC) opened at $16.35 on Tuesday. GlycoMimetics has a 1-year low of $3.82 and a 1-year high of $18.25.

GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.04. sell-side analysts forecast that GlycoMimetics will post -1.12 EPS for the current fiscal year.

In other GlycoMimetics news, SVP Helen M. Thackray sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $15.01, for a total value of $30,020.00. Following the sale, the senior vice president now directly owns 148,615 shares of the company’s stock, valued at $2,230,711.15. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 43.80% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at

GlycoMimetics Company Profile

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Insider Buying and Selling by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with's FREE daily email newsletter.